Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2006-10-17 09:25:06 UTC |
---|
Update Date | 2022-03-07 02:49:25 UTC |
---|
HMDB ID | HMDB0005026 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Rabeprazole |
---|
Description | Rabeprazole, also known as clofezone or eraloc, belongs to the class of organic compounds known as sulfinylbenzimidazoles. These are polycyclic aromatic compounds containing a sulfinyl group attached at the position 2 of a benzimidazole moiety. Rabeprazole is a drug which is used for the treatment of acid-reflux disorders (gerd), peptic ulcer disease, h. pylori eradication, and prevention of gastroinetestinal bleeds with nsaid use. In humans, rabeprazole is involved in the rabeprazole metabolism pathway. Rabeprazole is a primary metabolite. Primary metabolites are metabolically or physiologically essential metabolites. They are directly involved in an organism’s growth, development or reproduction. Based on a literature review a significant number of articles have been published on Rabeprazole. |
---|
Structure | COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3N2)=NC=C1 InChI=1S/C18H21N3O3S/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21) |
---|
Synonyms | Value | Source |
---|
Clofezone | ChEBI | Eraloc | Kegg | Aciphex | HMDB, MeSH | Habeprazole | HMDB | Pariet | HMDB, MeSH | Pariets | HMDB | Rabeprazole sodium | HMDB, MeSH | Sodium rabeprazole | HMDB | Dexrabeprazole | MeSH, HMDB | 1H-Benzimidazole, 2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-, sodium salt | MeSH, HMDB | 2-((4-(3-Methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1H-benzimidazole | MeSH, HMDB | Sodium, rabeprazole | MeSH, HMDB |
|
---|
Chemical Formula | C18H21N3O3S |
---|
Average Molecular Weight | 359.443 |
---|
Monoisotopic Molecular Weight | 359.130362243 |
---|
IUPAC Name | 2-{[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methanesulfinyl}-1H-1,3-benzodiazole |
---|
Traditional Name | rabeprazole |
---|
CAS Registry Number | 117976-89-3 |
---|
SMILES | COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3N2)=NC=C1 |
---|
InChI Identifier | InChI=1S/C18H21N3O3S/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21) |
---|
InChI Key | YREYEVIYCVEVJK-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as sulfinylbenzimidazoles. These are polycyclic aromatic compounds containing a sulfinyl group attached at the position 2 of a benzimidazole moiety. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Benzimidazoles |
---|
Sub Class | Sulfinylbenzimidazoles |
---|
Direct Parent | Sulfinylbenzimidazoles |
---|
Alternative Parents | |
---|
Substituents | - Sulfinylbenzimidazole
- Alkyl aryl ether
- Methylpyridine
- Pyridine
- Benzenoid
- Azole
- Imidazole
- Heteroaromatic compound
- Sulfoxide
- Sulfinyl compound
- Ether
- Dialkyl ether
- Azacycle
- Organic nitrogen compound
- Hydrocarbon derivative
- Organic oxide
- Organosulfur compound
- Organooxygen compound
- Organonitrogen compound
- Organopnictogen compound
- Organic oxygen compound
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Not Available | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 101.7 - 103.9 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Rabeprazole,1TMS,isomer #1 | COCCCOC1=CC=NC(CS(=O)C2=NC3=CC=CC=C3N2[Si](C)(C)C)=C1C | 3079.2 | Semi standard non polar | 33892256 | Rabeprazole,1TMS,isomer #1 | COCCCOC1=CC=NC(CS(=O)C2=NC3=CC=CC=C3N2[Si](C)(C)C)=C1C | 2996.9 | Standard non polar | 33892256 | Rabeprazole,1TMS,isomer #1 | COCCCOC1=CC=NC(CS(=O)C2=NC3=CC=CC=C3N2[Si](C)(C)C)=C1C | 3880.2 | Standard polar | 33892256 | Rabeprazole,1TBDMS,isomer #1 | COCCCOC1=CC=NC(CS(=O)C2=NC3=CC=CC=C3N2[Si](C)(C)C(C)(C)C)=C1C | 3219.6 | Semi standard non polar | 33892256 | Rabeprazole,1TBDMS,isomer #1 | COCCCOC1=CC=NC(CS(=O)C2=NC3=CC=CC=C3N2[Si](C)(C)C(C)(C)C)=C1C | 3206.9 | Standard non polar | 33892256 | Rabeprazole,1TBDMS,isomer #1 | COCCCOC1=CC=NC(CS(=O)C2=NC3=CC=CC=C3N2[Si](C)(C)C(C)(C)C)=C1C | 3908.5 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Rabeprazole GC-MS (Non-derivatized) - 70eV, Positive | splash10-009e-9843000000-7b2764dc90023b55c85c | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Rabeprazole GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Rabeprazole GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Rabeprazole 10V, Positive-QTOF | splash10-03dl-2159000000-f97510bdc8045ab08ca6 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Rabeprazole 20V, Positive-QTOF | splash10-006x-5792000000-af268bb77b35247f0f41 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Rabeprazole 40V, Positive-QTOF | splash10-00dl-9800000000-6bea6647768de1869c4d | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Rabeprazole 10V, Negative-QTOF | splash10-066r-1938000000-25678fb8a17be5befc29 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Rabeprazole 20V, Negative-QTOF | splash10-014i-0900000000-c503bc067607aca1451e | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Rabeprazole 40V, Negative-QTOF | splash10-014i-2910000000-aa7552fe843abc4a67e6 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Rabeprazole 10V, Negative-QTOF | splash10-0a4i-0119000000-c5f221b3ffcf7b5cc55c | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Rabeprazole 20V, Negative-QTOF | splash10-014i-0900000000-3214248b0f4d9b60f153 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Rabeprazole 40V, Negative-QTOF | splash10-014i-0900000000-9c4b8759dd61ba097216 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Rabeprazole 10V, Positive-QTOF | splash10-03di-0093000000-14b0419adbad3c76149e | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Rabeprazole 20V, Positive-QTOF | splash10-0229-1950000000-ce8b99f657880db6f1d0 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Rabeprazole 40V, Positive-QTOF | splash10-08ml-2910000000-2fbee5190b8417e0ac8a | 2021-09-22 | Wishart Lab | View Spectrum |
|
---|
Synthesis Reference | Souda, Shigeru; Ueda, Norihiro; Miyazawa, Shuhei; Tagami, Katsuya; Nomoto, Seiichiro; Okita, Makoto; Shimomura, Naoyuki; Kaneko, Toshihiko; Fujimoto, Masatoshi; et al. Preparation of 2-[(4-alkoxypyrid-2-yl)methylthio]benzimidazoles, -benzothiazoles, and -benzoxazoles as ulcer inhibitors. Eur. Pat. Appl. (1988), 96 pp. CODEN: EPXXDW EP 268956 A2 19880601 CAN 110:23889 AN 1989:23889 |
---|